Swiss Chemicals Stock News

In January 2026, VAT Group AG reported preliminary results showing fourth-quarter 2025 net sales of CHF 257 million, down from CHF 283.2 million a year earlier, while full-year 2025 net sales rose to CHF 1,073 million from CHF 942.2 million. An interesting detail is that preliminary fourth-quarter orders climbed to about CHF 305 million, growing both sequentially and year on year, even though full-year 2025 orders stayed roughly flat at around CHF 1,033 million. We will now examine how the...

Formula E and Google Cloud have entered a multi year AI partnership for the ABB FIA Formula E World Championship. Google Cloud becomes the Principal Artificial Intelligence Partner, providing tools such as digital twins and AI modeling for race operations and sustainability objectives. The agreement links ABB more closely with advanced data and AI use cases in next generation motorsport and electrification. For ABB (SWX:ABBN), this new AI focused partnership around the ABB FIA Formula E...

If you are wondering whether Roche Holding at CHF350.50 still offers value or if most of the upside is already priced in, you are in the right place. The stock has returned 1.1% over the last 7 days, 6.3% over 30 days, 7.7% year to date, 29.6% over 1 year, 35.7% over 3 years, and 32.7% over 5 years, which gives useful context before weighing up what you are paying today. Recent news around Roche has focused on its position in global pharmaceuticals and ongoing developments across its key...

Generally speaking long term investing is the way to go. But unfortunately, some companies simply don't succeed. To...

Swiss Life Holding AG recently presented at Citi's European Insurance Conference 2026 in London, offering investors fresh commentary from the insurer’s leadership on the sector and its positioning. This high-profile forum can give the market clearer visibility into management priorities and capital allocation thinking, potentially reshaping how Swiss Life’s long-term story is understood. We’ll now explore how Swiss Life’s appearance at Citi’s European Insurance Conference may influence its...

PolyPeptide Group AG recently reported preliminary 2025 figures pointing to about €389 million in revenue and an EBITDA margin of 11.0%–12.0%, supported by demand for metabolic therapeutics and ongoing capital spending. This early look at revenue and profitability offers investors an insight into how exposure to metabolic therapies may be reshaping PolyPeptide’s business mix ahead of its full audited 2025 results on 12 March 2026. Next, we’ll explore how this improved EBITDA margin guidance...

In January 2026, Geberit AG reported its full-year 2025 results, with currency-adjusted net sales up 4.8% and Swiss franc net sales rising 2.5% to CHF 3,163 million, clearly outpacing overall market development. This performance indicates that Geberit gained ground against competitors, as its sales growth meaningfully exceeded the broader market’s expansion in 2025. We will now examine how Geberit’s above-market 4.8% currency-adjusted sales growth shapes its investment narrative and future...

On 23 January 2026, Kuros Biosciences drew heightened investor attention as trading activity increased ahead of its 10 March 2026 earnings release and anticipated clinical updates in orthobiologics. The focus on MagnetOs and the fibrin/PTH spinal fusion and fracture programs highlights how upcoming medical data milestones may influence perceptions of the company’s pipeline progress. With a recent 7-day gain and interest in its fibrin/PTH program, we’ll examine how these developments shape...

In January 2026, Interroll announced the departure of Chief Operating Officer Ayan Demirel and Chief Technology Officer Dr. Johannes Van Der Beek, with CEO Markus Asch temporarily assuming operational leadership and industry veteran Ulrich Engenhardt joining as the new CTO. These simultaneous changes in operations and technology leadership highlight a pivotal moment for Interroll’s organisational direction, particularly around product platforms, regional capabilities and innovation...

Swiss Re has promoted Christophe Heck to market head Life Health for France, BeNeLux and Switzerland, based in Zurich and leading the group’s regional life and health reinsurance team. While this leadership move refines Swiss Re’s regional life and health focus, current investor attention appears more closely tied to the stock’s income appeal and upcoming earnings catalysts. Next, we’ll examine how Swiss Re’s income appeal and upcoming earnings update could influence the company’s broader...

Arctic pilot project puts dormakaba Holding (SWX:DOKA) in focus dormakaba Holding (SWX:DOKA) has started a pilot project at the Sorrisniva resort in Arctic Norway, testing its access systems in subzero conditions at the world’s northernmost ice hotel. The installation covers several parts of the resort and is intended to gather data on energy use and reliability, a development that has put the stock on some investors’ radars as they assess the business. See our latest analysis for dormakaba...

Key Insights Significant control over Cham Swiss Properties by retail investors implies that the general public has...

Key Insights Banque Cantonale de Genève's significant state or government ownership suggests that the key decisions are...

Partners Group Holding (SWX:PGHN) has launched a new global special opportunities strategy. The strategy is designed to provide flexible capital solutions in private markets. A newly appointed partner will lead the standalone strategy. The launch responds to liquidity driven opportunities arising from current macro conditions. Partners Group, a global private markets investment manager, is expanding its tool kit with this dedicated special opportunities strategy. For you as an investor, it...

Key Insights Significant control over Siegfried Holding by retail investors implies that the general public has more...

There wouldn't be many who think DocMorris AG's ( VTX:DOCM ) price-to-sales (or "P/S") ratio of 0.3x is worth a mention...

Why Swiss Re is on watchlists ahead of earnings Swiss Re (SWX:SREN) is drawing increased attention as investors look ahead to its 27 February 2026 earnings release, focusing on the stock’s 4.75% dividend yield and recent trading activity. See our latest analysis for Swiss Re. Recent trading has been choppy, with a 30 day share price return of 7.39% and a 90 day share price return of an 18.66% decline. The 5 year total shareholder return of 111.08% points to momentum that has built over a...

India Energy Week debut puts Sensirion Holding (SWX:SENS) gas metering in focus Sensirion Holding (SWX:SENS) is drawing attention after announcing its first participation at India Energy Week 2026, where it will showcase its thermal mass gas metering technology and newly introduced SGM5304 gas meter module. The event spotlights Sensirion's role in gas metering, with more than 11 million meters installed globally and certification under harmonized standard EN 17526, as investors consider the...

In January 2026, BKW AG held a special call to lower its 2025 EBIT guidance to CHF 540 million–CHF 560 million and introduce a 2026 EBIT range of CHF 650 million–CHF 750 million. This shift in near-term expectations versus a higher 2026 outlook highlights how BKW is recalibrating its earnings profile over the next two years. Next, we will examine how BKW’s reduced 2025 EBIT guidance shapes the company’s investment narrative and risk-reward profile for investors. Trump has pledged to...

Holcim (SWX:HOLN) came into focus after Goldman Sachs shifted its view on the shares from Buy to Neutral, following a strong rally that left the valuation looking full. See our latest analysis for Holcim. The latest CHF78.0 share price comes after a small 1 day share price decline, but that follows an 11.65% 90 day share price return and a very strong 1 year total shareholder return of 73.76%, pointing to momentum that has been building over a longer horizon. That performance also aligns with...

As the European markets show resilience with the STOXX Europe 600 Index ending higher, supported by robust economic data and earnings results, investors are keenly observing opportunities for undervalued stocks amidst mixed performances across major indices. In this context, identifying stocks trading below their intrinsic value can be a strategic move for those looking to capitalize on potential market inefficiencies.

In January 2026, Sandoz confirmed that the European Commission had granted marketing authorization for Ondibta®, a biosimilar insulin glargine pre-filled pen for patients with diabetes aged two and above, matching Lantus® SoloStar® in safety, quality and efficacy. This approval, under Sandoz’s commercialization agreement with Gan & Lee, reinforces its biosimilar footprint in diabetes care and supports broader access to insulin across Europe. We will now examine how this European Commission...

In mid-January 2026, analysts from Kepler Capital and Goldman Sachs reiterated Hold views on Swissquote Group Holding while independent Meyka AI issued a positive rating, citing the company’s AI-driven client automation and personalised trading tools alongside resilient 2025 preliminary results. The commentary underscores how Swissquote’s use of AI, combined with robust net income resilience and ongoing client flows into crypto and margin products, is shaping a differentiated growth story...

Logitech International (SWX:LOGN) has introduced its Rally AI Camera and Rally AI Camera Pro, two AI-powered conference cameras. The new products focus on room usage detection, sustainability features, and integration into managed network environments. The launch marks an expansion of Logitech's video collaboration portfolio aimed at enterprise and education customers. For Logitech, known for its peripherals and video collaboration gear, the Rally AI Camera line extends its presence in...